Liminatus Pharma shares fall 9.85% intraday despite announcing a $500 million BNB investment strategy.

Liminatus Pharma, Inc. declined 9.85% intraday, despite announcing plans to launch a new subsidiary, 'American BNB Strategy,' to invest up to $500 million in BNB cryptocurrency. The company aims to aggressively accumulate and hold the digital asset for long-term strategic value. However, the broader market sentiment, as indicated by the global markets rising due to trade deal progress, did not seem to positively influence Liminatus Pharma's stock price.